Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in severe asthma patients eligible for both

Pfeffer, P, Ali, N, Murray, R, Ulrik, C, Tran, T, Maspero, J, Peters, M, Christoff, G, Sadatsafavi, M, Torres-Duque, C A, Altraja, A, Lehtimäki, L, Papadopoulos, N, Salvi, S, Costello, R W, Cushen, B, Heffler, E, Iwanaga, T, Al-Ahmad, M, Larenas-Linnemann, D, Kuna, P, Fonseca, J, Al-Lehebi, R, Rhee, C K, Llano, L P D, Perng, D-W, Mahboub, B, Wang, E, Goh, Y Y C, Lyu, J, Newell, A, Alacqua, M, Bhutani, M, Bjermer, L, Björnsdóttir, U S, Bourdin, A, Bülow, A V, Busby, J, Canonica, W, Cosio, B G, Dorscheid, D, Esquerre, M M, FitzGerald, M, Gil, E G, Gibson, P G, Heaney, L, Hew, M, Hilberg, O, Hoyte, F, Jackson, D, Koh, M, Ko, H-K, Lee, J H, Lehmann, S, Loureiro, C C, Ludviksdottir, D, Menzies-Gow, A, Mitchell, P, Papaioannou, A, Popov, T, Porsbjerg, C, Salameh, L, Sirena, C, Taillé, C, Taube, C, Tohda, Y, Wechsler, M E & Price, D 2023, 'Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in severe asthma patients eligible for both', Allergy, vol. 78, no. 7, pp. 1934-1948. https://doi.org/10.22541/au.166563547.79282253/v1, https://doi.org/10.1111/all.15711